Managing Elacestrant Treatment: From Patient Selection to Supportive Care

EP: 1.Understanding Cancer Changes and Testing: How Testing Guides Your Metastatic Breast Cancer Treatment

EP: 2.Navigating Treatment After Progression: Testing, ESR1 Mutations and Tolerable Options

EP: 3.Exploring a Patient Case: Biomarker Testing After Progression and Discussing Treatment Choices With Your Care Team

EP: 4.EMERALD Trial Results: What Prior CDK4/6i Duration Means for Treatment Success

Now Viewing

EP: 5.Managing Elacestrant Treatment: From Patient Selection to Supportive Care

EP: 6.Real-World Experience: The Efficacy and Tolerability of Oral Elacestrant for Patients with ESR1 Mutations

EP: 7.Patient Education, Shared Decision-Making, and Optimizing Care for ESR1-Mutated Breast Cancer

Clinical Brief: Second-Line Treatment Decision Framework

Main Discussion Topics:

Integration of patient factors in treatment selection

Balance between efficacy and quality-of-life considerations

Practical considerations: insurance, copays, administration route

Sequential versus concurrent treatment strategies

Role of shared decision-making in complex treatment landscape

Key Points for Physicians:

Treatment selection requires balance of clinical trial data with patient-specific factors

Consider timing of treatments (when versus if to use each therapy)

Patient preferences regarding administration route can influence decisions

Functional status and treatment urgency guide sequencing strategy

Financial and logistical factors play significant role in real-world decisions

The experts emphasized that second-line therapy decisions require integrating scientific evidence with individualized patient assessment, considering medical and practical factors.